DIA, Arlington, VA 22204
Apr 11 2010 8:00AM - Apr 13 2010 5:00PM
Date(s) And Time(s):
Apr 11 2010 8:00AM - Apr 13 2010 5:00PM
Location:
Sheraton National Hotel Arlington
900 South Orme Street
Arlington, VA 22204
Interest Area(s):
Clinical Safety/Pharmacovigilance, Clinical Research, Document Management/ eSubmissions, Nonclinical, Quality Assurance/Quality Control, Regulatory Affairs, Research & Development
Overview:
Abstract Submission Guidelines Please submit all abstracts via email to Rachel Minnick, Program Developer Rachel.Minnick@diahome.org All abstracts must be received by February 13, 2010 Authors of selected abstracts will be notified by March 13, 2010 Suggested Abstract Topics (The strongest abstracts have been those with a clear hypothesis and supporting data with a strong scientific design) Drug Development and CV safety · Drug-induced increases in CV events · Myocardial toxicity · Pharmacogenomics and drug-induced CV injury · How can we practically assess the negative inotropic potential of new drugs? · Anticoagulant safety—how to measure it? Evolving Science of QT/Arrhythmia Assessment
Target Audience:
Who Should Attend · Academic scientists · Industry management · Clinical project physicians · Quality assurance directors · Preclinical/discovery scientists · ECG safety data managers · ECG lab and equipment vendors · Regulatory specialists
|
